- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Epicyn gel wins derm indication
The Food and Drug Administration has approved Epicyn HydroGel (Oculus Innovative Sciences) for treatment of various dermatoses and burns, MedPage Today reports.
Washington - The Food and Drug Administration has approved Epicyn HydroGel (Oculus Innovative Sciences) for treatment of various dermatoses and burns, MedPage Today reports.
The agency approved the gel as a medical device. The gel is now indicated for treatment of burning, itching and pain associated with atopic and radiation dermatitis, as well as for pain resulting from first- and second-degree burns.
According to an Oculus statement, the gel also maintains “a moist wound and skin environment” to help treat dry and waxy skin.
Available only by prescription, Epicyn HydroGel is based on Oculus’ Microcyn oxychlorine compound and is a shelf-stable hypochlorous acid formulation.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
